TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16706692
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg orally, twice a day for 21 days (chronic pyrophosphate arthropathy)
Study: 16706692
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg orally, twice a day for 21 days (chronic hydroxyapatite arthropathy)
Study: 11103185
Drug: Propofol 6‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 6‐8 mg kg‐1 h‐1
Study: 3534317
Drug: Phenoxybenzamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine (10 mg, orally twice daily for 3 days)
Study: 3534317
Drug: Carbachol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbachol (2 mg, orally twice daily for 3 days)
Study: 3534317
Drug: Placebo (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally twice daily for 3 days)
Study: 3076867
Drug: Tetracycline eye
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline eye ointment, twice daily for five days each month for six months
Study: 3076867
Drug: Oral doxycycline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline, 5 mg/kg body weight weekly for three weeks
Study: 3076867
Drug: Oral sulphametopyrazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulphametopyrazine, 35 mg/kg body weight weekly for three weeks
Study: 23237736
Drug: Low-dose vaporized
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaporized cannabis (1.29%)
Study: 23237736
Drug: Medium-dose vaporized
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose vaporized cannabis (3.53%)
Study: 9316509
Drug: Probucol (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1,000 mg/day)
Study: 15059707
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no lipid-lowering therapy)
Study: 8403306
Drug: Ketanserin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (loading dose, 40 mg 1 hour before PTCA; maintenance dose, 40 mg bid for 6 months)
Study: 3094627
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (active drug)
Study: 29673395
Drug: 4-month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Study: 29673395
Drug: 6-month regimen
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month regimen using revised WHO paediatric anti-tuberculosis drug doses
Study: 28606567
Drug: Wellmune 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellmune 250 mg/d
Study: 26520140
Drug: Delayed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed intervention group receiving periodontal treatment 24 months after baseline.
Study: 23735703
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (PRE)
Study: 23735703
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PERI)
Study: 16567126
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean dose 154 mg)
Study: 16567126
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean dose 158 mg)
Study: 14565651
Drug: No cytokine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cytokine treatment
Study: 10425883
Drug: Klebsiella pneumoniae
Normalized name: Klebsiella pneumoniae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klebsiella pneumoniae glycoproteins extract (1 g/day for one week a month for three months)
Study: 2197428
Drug: Ethoglucid (0.565
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethoglucid (0.565 gm, solution of 1%) weekly for 6 weeks, then monthly for 1 year
Study: 2197428
Drug: Keyhole‐limpet hemocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole‐limpet hemocyanin (1 mg intracutaneously, then 30 mg bladder instillations weekly for 6 weeks, then monthly for 1 year)
Study: 24699062
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of ketamine (0.5 mg/kg)
Study: 22149464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only physical therapy and rehabilitation (PTR) for 4 weeks
Study: 20798227
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with TSH<0.3 mIU/l
Study: 20798227
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with TSH>10 mIU/l
Study: 17700388
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg weekly
Study: 26185417
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg weekly
Study: 26185417
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg weekly
Study: 17700388
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg every other week
Study: 17700388
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg every other week
Study: 16135896
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg QD
Study: 16135896
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BID
Study: 16135896
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg QD
Study: 16135896
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg BID
Study: 11906322
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg thioctic acid
Study: 19124377
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg
Study: 2541740
Drug: Converting‐enzyme inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting‐enzyme inhibitor (CEI)
Study: 29551330
Drug: increase moderate
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: increase moderate to vigorous physical activity (MVPA) treatment group
Study: 28070018
Drug: Curcumin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (2000 mg/day Longvida®; n=20)
Study: 12053590
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 or 10 mg)
Study: 2156706
Drug: Intravenous urography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urography (IVU)
Study: 9038591
Drug: Exogenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous insulin (50 m-units h-1 kg-1) for 4 hours
Study: 1000140
Drug: Aversive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aversive therapy
Study: 25653574
Drug: Edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 15 mg once daily
Study: 22699104
Drug: High-dosage CIMT
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage CIMT (6 hours/day for 21 days, total 126 hours)
Study: 22699104
Drug: Moderate-dosage CIMT
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dosage CIMT (3 hours/day for 21 days, total 63 hours)
Study: 12088951
Drug: Intraoperative small-dose
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative small-dose ketamine (0.15 mg/kg followed by 2 microg. kg(‐1). min(‐1))
Study: 10334526
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 i.v. every 3 weeks (n=203)
Study: 10334526
Drug: Mitomycin 12
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 12 mg/m2 i.v. every 6 weeks plus vinblastine 6 mg/m2 i.v. every 3 weeks (n=189)
Study: 7604138
Drug: Nicergoline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (2 x 30 mg)
Study: 21993319
Drug: Intravenous urography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urography and renal ultrasonography (no CT scan)
Study: 16239317
Drug: Mild ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild ovarian stimulation with GnRH antagonist co-treatment and transfer of one embryo
Study: 16239317
Drug: Conventional stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stimulation with GnRH agonist long protocol co-treatment and transfer of two embryos
Study: 21214105
Drug: Amiodarone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (5 mg/kg)
Study: 9005747
Drug: 10-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg loading dose of warfarin
Study: 9005747
Drug: 5-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg loading dose of warfarin
Study: 27978942
Drug: Recommended NOAC
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended NOAC doses
Study: 22372543
Drug: Combined superficial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined superficial & deep fractional skin treatment using a 120‐micron, focused CO(2) laser beam
Study: 22372543
Drug: Combined superficial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined superficial & deep fractional skin treatment
Study: 15708690
Drug: Fludrocortisone 0.1
Normalized name: fludrocortisone 0.1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.1 mg/day and salt 1 g/day
Study: 1737735
Drug: Low-dose intranasal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intranasal midazolam (0.25 to 0.5 mg)
Study: 6390057
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 micrograms/kg to 100 micrograms/kg) + MPSS (30 mg/kg)
Study: 6390057
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of naloxone (30 micrograms/kg) + continuous infusion (30 micrograms/kg/hr for 1 hour) + MPSS (30 mg/kg)
Study: 6390057
Drug: Naloxone (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (bolus and continuous infusion) without MPSS
Study: 6390057
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose bolus and continuous infusion of naloxone + MPSS
Study: 27011266
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 1 mg/kg/day, tapering by 5 mg/day, for 2 weeks
Study: 27011266
Drug: Intrapolyp steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapolyp steroid injection (40 mg/mL triamcinolone, 1 mL) for up to five times with intervals of 1 week
Study: 21947706
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg daily after EVL
Study: 21947706
Drug: No antisecretory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antisecretory treatment
Study: 19411667
Drug: Phenylephrine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine at a rate of 16.6 microg min(‐1) (concentration 1 microg ml(‐1))
Study: 19411667
Drug: Ephedrine at
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine at a rate of 1.5 mg min(‐1) (concentration 90 microg ml(‐1))
Study: 16549920
Drug: Leflunomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally)
Study: 9930393
Drug: Psychotherapy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy in addition to corticosteroid treatment
Study: 9930393
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment alone (Control)
Study: 3519731
Drug: Streptokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase therapy
Study: 7850822
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (general)
Study: 29848776
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor (alogliptin)
Study: 27272083
Drug: Naftifine cream
Normalized name: naftifine Topical Cream
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine cream 2%
Study: 24071565
Drug: Testosterone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (0.5 mg single dose)
Study: 18343652
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 IU, subcutaneously, once weekly) initiated within 7 days of the start of the first chemotherapy cycle
Study: 18343652
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (epoetin alfa when Hb <= 10 g/dL)
Study: 10701699
Drug: Nevirapine 15
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine 15 mg via short‐term i.v. infusion
Study: 10701699
Drug: Nevirapine 50
Normalized name: nevirapine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 50 mg tablet
Study: 10701699
Drug: Nevirapine oral
Normalized name: nevirapine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine oral reference solution (50 mg/200 mL)
Study: 10701699
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg production‐line tablet
Study: 10701699
Drug: Nevirapine oral
Normalized name: nevirapine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine oral reference solution (200 mg/200 mL)
Study: 8634003
Drug: Psychotherapy (cognitive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (cognitive, behavioral, brief psychodynamic, and group therapies)
Study: 8634003
Drug: Combined psychotherapy-pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psychotherapy-pharmacotherapy regimens
Study: 1773125
Drug: Permethrin-impregnated bednets
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin-impregnated bednets (500 mg/m2)
Study: 1773125
Drug: Blank formulation
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank formulation (similar to EC without permethrin)
Study: 1773125
Drug: Lambda-cyhalothrin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambda-cyhalothrin (25 mg/m2)
Study: 1773125
Drug: Permethrin (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin (5, 50, or 500 mg/m2)
Study: 6764605
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SL-76188
Study: 6764605
Drug: 175 mg
Normalized name: caffeine 175 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg SL-76188
Study: 6764605
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg SL-76188
Study: 19727679
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg D-amphetamine
Study: 20589515
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg plus diazepam
Study: 19451213
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen therapy (ET)
Study: 10386529
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) titrated from 100 mg/day over 6 weeks
Study: 10386529
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) titrated from 200 mg/day
Study: 8885910
Drug: 17-beta-estradiol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol 2 mg alone
Study: 8885910
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with norethisterone 1 mg
Study: 6405877
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with spontaneous ventilation
Study: 6405877
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with controlled ventilation
Study: 30907301
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9 mg/kg)
Study: 23000080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic exercise and DASH diet for 6 months
Study: 16364829
Drug: BQ-123 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (0.1, 0.2, and 0.3 mg/kg for 1 h)
Study: 12059866
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% and Brimonidine 0.2% (concomitant therapy)
Study: 12059866
Drug: Brimonidine and
Normalized name: brimonidine and ripasudil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine and Timolol/Brimonidine (concomitant treatment)
Study: 8628712
Drug: Broad spectrum
Normalized name: Broad spectrum penicillin
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Broad spectrum antibiotics
Study: 1869979
Drug: Dipyridamole infusion
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole infusion alone
Study: 6139346
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zetidoline
Study: 6139346
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg zetidoline
Study: 6139346
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg haloperidol (positive control)
Study: 29737150
Drug: Antispasmina col
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antispasmina col forte (50 mg papaverine hydrochloride + 10 mg belladonna extract when needed)
Study: 29737150
Drug: Buscopan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buscopan (10 mg when needed)
Study: 22374556
Drug: DL-alpha-lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-alpha-lipoic acid (ALA) 300, 600, 900, and 1200 mg/day for 6 months
Study: 17038827
Drug: Nasal, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal, inactivated trivalent influenza virus vaccine (7.5, 15, or 30 microg hemagglutinin antigen)
Study: 17038827
Drug: Nasal, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal, inactivated trivalent influenza virus vaccine (30 microg hemagglutinin antigen)
Study: 10486372
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment after evaluation with EUS and endoscopy
Study: 2127723
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) during the immediate postoperative period (Group I)
Study: 2127723
Drug: Conventional serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional serum therapy during the immediate postoperative period (Group II)
Study: 145840
Drug: Apomorphine hydrochloride
Normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine hydrochloride (1 to 4 mg intramuscularly)
Study: 145840
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg intramuscularly) or Sulpiride (100 mg intramuscularly) pretreatment
Study: 30650286
Drug: Conventional hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypoglycemic therapy
Study: 18472356
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy plus adjuvant chemotherapy (CRT)
Study: 8039526
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drugs
Study: 8706291
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol patches, 0.05 mg/day
Study: 8706291
Drug: Subdermal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal implants containing 50 mg oestradiol
Study: 8706291
Drug: Subdermal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal implants containing 50 mg oestradiol with 100 mg testosterone
Study: 1647495
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg sumatriptan
Study: 1647495
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg or 8 mg)
Study: 31242976
Drug: Cisplatin (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (Arm A) - 100 mg/m² 3-weekly or 40 mg/m² weekly during radiation
Study: 31242976
Drug: Cetuximab (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (Arm B) - loading dose 400 mg/m² one week before radiation followed by 250 mg/m² weekly during radiation
Study: 25344383
Drug: Acitretin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (30 mg per day)
Study: 20974089
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (n=6), attended classes once a week and practiced 10 minutes daily for 15 weeks
Study: 15807740
Drug: Topical adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adapalene gel (0.1%)